SR

Shakuntalaben Ramanlal Damor

Active Director Director DIN 08282155
DIN 08282155 First appointment Nov 2018 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Shakuntalaben Ramanlal Damor

Data last updated:

Shakuntalaben Ramanlal Damor is a Director at Geniussky Pharmaceutical Private Limited (since 2018). The company operates in Pharma.

DIN 08282155
Primary Designation Director
Industry Pharma
First Appointment 20 Nov 2018
Oldest Company Age 9 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Nov 20182017Active

Board colleagues of Shakuntalaben Ramanlal Damor

NameDINCompanyDesignation
Nisarg Ramanlal Damor08282153Geniussky Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Geniussky Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Shakuntalaben Ramanlal Damor

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shakuntalaben Ramanlal Damor

Shakuntalaben Ramanlal Damor currently holds 1 directorship: Geniussky Pharmaceutical Private Limited (Director, since 20 Nov 2018).

Shakuntalaben Ramanlal Damor was first appointed on 20 Nov 2018 as Director at Geniussky Pharmaceutical Private Limited.

The current boards of Shakuntalaben Ramanlal Damor's companies include Nisarg Ramanlal Damor (Geniussky Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available